Display options
Cite
Jain D, Gangshettiwar A. Combination of lycopene, quercetin and poloxamer 188 alleviates anxiety and depression in 3-nitropropionic acid-induced Huntington's disease in rats. J Intercult Ethnopharmacol. 2014;3(4):186-91doi: 10.5455/jice.20140903012921.
Jain, D., & Gangshettiwar, A. (2014). Combination of lycopene, quercetin and poloxamer 188 alleviates anxiety and depression in 3-nitropropionic acid-induced Huntington's disease in rats. Journal of intercultural ethnopharmacology, 3(4), 186-91. https://doi.org/10.5455/jice.20140903012921
Jain, Dilpesh, and Gangshettiwar, Arti. "Combination of lycopene, quercetin and poloxamer 188 alleviates anxiety and depression in 3-nitropropionic acid-induced Huntington's disease in rats." Journal of intercultural ethnopharmacology vol. 3,4 (2014): 186-91. doi: https://doi.org/10.5455/jice.20140903012921
Jain D, Gangshettiwar A. Combination of lycopene, quercetin and poloxamer 188 alleviates anxiety and depression in 3-nitropropionic acid-induced Huntington's disease in rats. J Intercult Ethnopharmacol. 2014 Oct-Dec;3(4):186-91. doi: 10.5455/jice.20140903012921. Epub 2014 Sep 12. PMID: 26401371; PMCID: PMC4576812.
Copy Download .nbib Format: NLM
Share it on

J Intercult Ethnopharmacol. 2014 Oct-Dec;3(4):186-91. doi: 10.5455/jice.20140903012921. Epub 2014 Sep 12.

Combination of lycopene, quercetin and poloxamer 188 alleviates anxiety and depression in 3-nitropropionic acid-induced Huntington's disease in rats.

Journal of intercultural ethnopharmacology

Dilpesh Jain, Arti Gangshettiwar

Affiliations

  1. Department of Pharmacology, Sinhgad College of Pharmacy, Vadgaon (Bk.), Pune, Maharashtra, India.

PMID: 26401371 PMCID: PMC4576812 DOI: 10.5455/jice.20140903012921

Abstract

AIM: The present study investigates synergistic effect of combination treatment of lycopene, quercetin and poloxamer188 in 3-nitropropionic acid (3-NP)-induced Huntington's disease (HD).

MATERIALS AND METHODS: Anxiety and depression were induced in male Wistar rat by intra-peritoneal administration of 3-NP (10 mg/kg) for 14 days. Body weight was assessed on day 1, 7 and 14, whereas locomotion, anxiety and depression were assessed at the end of the experiment.

RESULTS: Administration of 3-NP induces HD like symptoms and produced a significant decrease in body weight on day 7 (P < 0.01)and day 14 (P < 0.001), further decreased locomotion, time spent and number of entries in light area as well as increased immobility period were observed. The rats treated with lycopene and quercetin alone significantly restore the body weight and locomotion count as well as alleviate anxiety and depression. However, combination treatment of lycopene and quercetin with and without poloxamer 188 produced more significant effect on body weight compared to Huntington control rats, but no significant effect was found between the treated groups. However, significant increased on locomotion, time spent and number of entries in light area and decreased immobility period was observed in the combination treated groups when compared to single drug therapy.

CONCLUSION: Combination treatment of lycopene and quercetin with and without poloxamer 188 in HD more effectively alleviate anxiety and depression than single drug therapy.

Keywords: 3-nitropropionic acid; Huntington disease; lycopene; quercetin

References

  1. Nat Rev Drug Discov. 2004 Mar;3(3):205-14 - PubMed
  2. Toxicology. 2005 Jan 31;206(3):337-48 - PubMed
  3. Cell Biochem Funct. 2008 Dec;26(8):881-91 - PubMed
  4. Life Sci. 1999;65(4):337-53 - PubMed
  5. J Pharmacol Pharmacother. 2010 Jan;1(1):24-31 - PubMed
  6. J Neurosci. 2002 Mar 15;22(6):2174-84 - PubMed
  7. Int J Appl Basic Med Res. 2011 Jul;1(2):104-8 - PubMed
  8. Neuropsychiatry Neuropsychol Behav Neurol. 2001 Oct-Dec;14(4):219-26 - PubMed
  9. Hum Genet. 1992 Jun;89(4):365-76 - PubMed
  10. Eur J Clin Nutr. 2007 Mar;61(3):295-303 - PubMed
  11. Cell. 1996 Nov 1;87(3):493-506 - PubMed
  12. Nature. 1983 Nov 17-23;306(5940):234-8 - PubMed
  13. Curr Mol Med. 2008 May;8(3):221-34 - PubMed
  14. Neurology. 1992 Sep;42(9):1791-7 - PubMed
  15. Eur J Pharmacol. 2007 Jul 2;566(1-3):192-9 - PubMed
  16. Eur J Pharmacol. 2003 Dec 15;482(1-3):281-5 - PubMed
  17. Nutr Neurosci. 2011 May;14(3):106-11 - PubMed
  18. J Neurol Neurosurg Psychiatry. 2001 Sep;71(3):310-4 - PubMed
  19. Free Radic Biol Med. 2001 Mar 1;30(5):456-62 - PubMed
  20. Nutr Clin Care. 2002 Mar-Apr;5(2):56-65 - PubMed
  21. J Neurosci. 1997 May 1;17(9):3064-73 - PubMed
  22. Recent Pat Biotechnol. 2012 Dec;6(3):200-11 - PubMed
  23. Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R1071-7 - PubMed
  24. Neurol India. 1999 Dec;47(4):340-1 - PubMed
  25. J Neurosci. 2013 Feb 27;33(9):4206-10 - PubMed
  26. Trends Neurosci. 2001 Mar;24(3):182-8 - PubMed
  27. Physiol Behav. 1986;38(3):385-6 - PubMed
  28. Stroke. 2000 Oct;31(10):2301-6 - PubMed
  29. Nature. 2014 May 1;509(7498):96-100 - PubMed
  30. Eur J Pharmacol. 2009 Sep 1;617(1-3):74-8 - PubMed
  31. Psychopharmacology (Berl). 1998 Apr;136(3):291-8 - PubMed
  32. Pharmacogn Rev. 2013 Jul;7(14):81-91 - PubMed
  33. Neurochem Int. 1996 Aug;29(2):167-71 - PubMed
  34. Life Sci. 2009 Nov 4;85(19-20):711-8 - PubMed
  35. Lancet. 2007 Jan 20;369(9557):218-28 - PubMed
  36. Front Behav Neurosci. 2014 Apr 23;8:135 - PubMed
  37. Curr Pharm Des. 2008;14(32):3430-45 - PubMed
  38. Biochim Biophys Acta. 2013 Mar;1832(3):421-30 - PubMed
  39. Neuroscience. 2001;105(1):153-67 - PubMed
  40. Neurology. 2008 Nov 4;71(19):1506-13 - PubMed
  41. J Proteome Res. 2011 Apr 1;10(4):2079-87 - PubMed

Publication Types